New Serum-Peel combo aims to fade dark spots and wrinkles
NCT ID NCT07429786
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding MELA B3 serum to a 35% glycolic acid peel works better than the peel alone for treating dark spots (melasma, post-acne marks, age spots) and signs of aging. About 80 adults aged 30-70 in Buenos Aires will use the treatments for 3 months. The goal is to see if the combination improves skin tone, fine lines, and firmness more effectively.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 80 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Mar 2026
An estimate. Start dates often move.
- Expected to finish
-
Jun 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
30 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Women and men 2. From 30 to 70 years of age (inclusive) 3. Good general health 4. With any type of phototype 5. Hyperpigmentation condition with average darkness \> 3: 1. Epidermal or mixed melasma (determined by Wood's lamp examination at screening), mild to moderate melasma (IGA 1 or 2) 2. Post acne inflammatory hyperpigmentation (PIHP), mild to moderate (IGA 1 or 2) with no active acne and less than 10 inflammatory lesion on full face 3. Solar lentigo (SL) with a pigmentation score\>5 6. Willingness to protect oneself from the sun as much as possible for the duration of the study 7. Willingness to avoid contraindicated products (irritants, other depigmenting agents) 8. Signing of written informed consent Exclusion Criteria: 1. Pregnant, breastfeeding or with pregnancy plans. 2. All contraindications for superficial peeling (for example, concomitant infectious processes or inflammatory processes that affect the skin barrier). 3. Melasma with predominance of the pigmentary component at the dermis level, observed with Wood's light at the inclusion visit. 4. Active acne with 10 or more inflammatory lesions. 5. In the case of melasma, participants with recent change of contraception (less than 3 months) or less than 3 months since childbirth. 6. Participant using irritating products (require a washout period of at least 2 weeks). 7. Use of medications that may induce melasma, such as antiepileptics (requires a washout period of 1 month). 8. Use of other products with depigmenting activity (requires a washout period of 1 month). 9. Other facial dermatoses or known photosensitivity, or a pre-existing or latent dermatologic health condition and/or disease on the face (e.g., psoriasis, rosacea, acne, eczema, seborrheic dermatitis, severe excoriations) that, in the judgment of the investigator, are considered inappropriate for participation or may interfere with study results. 10. Topical treatments applied to the face (requires a 2-week washout period). 11. Scheduled facial procedures during the course of the study. 12. Participants undergoing phototherapy (requires a 1-month washout period). 13. Known hypersensitivity to study products. 14. History of laser resurfacing procedures, intense pulsed light, facial radiofrequency, deep peeling, facial mesotherapy with tranexamic acid, botulinum toxin or dermal filler injections, or cosmetic procedures on the face within 6 months prior to the start of the study. 15. Facial treatment with microdermabrasion within 6 weeks prior to study entry. 16. Persons with visible tanning, scars, moles, excessive hair or other dermal conditions on the face that, in the judgment of the investigator, may influence the results of the study. 17. History of skin cancer, immunosuppression or immunodeficiency disorders (including HIV infection or AIDS), or current use of immunosuppressive drugs. 18. Uncontrolled disease such as asthma, diabetes, hypertension, hyperthyroidism or hypothyroidism. Persons with multiple health conditions may be excluded, even if controlled by diet or medication. 19. Participation in another clinical trial within one week prior to entering this study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hyperpigmentation are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Apple peptides may speed skin healing after cosmetic procedures
- Can stem cell exosomes fade melasma patches?
- Can seaweed microspicules turn back the clock on aging skin?
- A new gel aims to fade dark Spots—Will it deliver a brighter complexion?
- Can a new laser erase acne scars without harming darker skin?
- Can a simple pill make melasma creams work better?